Upon joining the study, eligibility is confirmed based on specific criteria, including age, diagnosis of ulcerative colitis, and previous treatment history.

A surveillance colonoscopy must have been performed within one year prior to the start of the study to rule out dysplasia or colon cancer.

Initial assessments are conducted to establish baseline measurements. This includes a review of medical history and current symptoms.

Participants are required to complete electronic diary entries to document symptoms and bowel movements.

Participants receive either rosnilimab or a placebo. Rosnilimab is administered as a solution for injection under the skin (subcutaneous).

The frequency and dosage of the injections are determined by the study protocol and are administered regularly throughout the trial.

Regular assessments are conducted to monitor the effectiveness and safety of the treatment. This includes measuring changes in symptoms and conducting endoscopic evaluations.

Participants are monitored for any side effects or adverse events, and adjustments to the treatment may be made if necessary.

At the end of the treatment period, a final evaluation is conducted to assess the overall impact of the treatment on ulcerative colitis symptoms.

This includes a comprehensive review of all collected data, including symptom diaries, endoscopic results, and any side effects experienced.

Participants may be required to attend follow-up visits to monitor long-term effects and gather additional data on the treatment’s impact.

These visits help ensure the continued safety and well-being of participants after the trial concludes.